Bellmunt, Joaquim http://orcid.org/0000-0003-2328-3421
Lalani, Aly-Khan A. http://orcid.org/0000-0002-9907-9112
Jacobus, Sussana
Wankowicz, Stephanie A.
Polacek, Laura
Takeda, David Y.
Harshman, Lauren C. http://orcid.org/0000-0002-7636-1588
Wagle, Nikhil
Moreno, Irene
Lundgren, Kevin
Bossé, Dominick
Van Allen, Eliezer M.
Choueiri, Toni K. http://orcid.org/0000-0002-9201-3217
Rosenberg, Jonathan E.
Article History
Received: 5 April 2018
Revised: 15 August 2018
Accepted: 23 August 2018
First Online: 17 September 2018
Competing interests
: J.B.: Honoraria/consulting from Astellas, Genentech, Merck, Novartis, Pfizer, Pierre Fabre; institutional research funding/support from Millenium, Sanofi, MSD Oncology, Pfizer. A.A.L.: Honoraria/consulting from Novartis; travel expenses from Pfizer. L.C.H.: Honoraria/consulting from Genentech, Pfizer, Dendreon, NCCN, Medivation/Astellas, KEW; institutional research funding/support from Bayer, Medivation/Astellas, Pfizer, Dendreon, Sotio, Genentech, Merck, BMS, Jannsen. E.M.V.A.: Honoraria/consulting from Genome Medical, Novartis, Roche, Syapse, Takeda, Third Rock Ventures; institutional research funding/support from Bristol-Myers Squibb, Novartis. T.K.C.: Honoraria/consulting from Alligent, AstraZeneca, Bayer, Bristol-Myers Squibb, Cerulean Pharma, Eisai, Exelixis, Foundation Medicine, GlaxoSmithKline, Merck, Novartis, Peloton, Pfizer, Prometheus, Roche/Genentech; institutional research funding/support from Pfizer, Exelixis, Bristol-Myers Squibb, Novartis, Peloton, AstraZeneca, Agensys, TRACON. J.E.R.: Honoraria/consulting from Agensys, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol- Myers Squibb, EMD Serono, Lilly, Merck, Oncogenex, Roche/Genentech, Sanofi, Seattle Genetics; institutional research funding/support from Agensys, Genentech/Roche, Mirati Therapeutics, Novartis, Oncogenex, Viralytics. The remaining authors declare no competing interests.
: The study was conducted with Dana-Farber/Harvard Cancer Center institutional review board approval in accordance with the Declaration of Helsinki and Good Clinical Practice and was registered with the National Institutes of Health (NCT01184326). Patients provided informed consent.
: All data and materials are available upon request.
: This work was supported by Novartis in the setting of an Investigator Initiated Study.
: This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).